|Day's range||0.0800 - 0.0800|
Collaboration will extend the applications of each company’s platform through discovery and development of novel lipid nanoparticles using Generation Bio’s proprietary stealth cell-targeted lipid nanoparticle (ctLNP) delivery system Moderna has acquired an option to license Generation Bio’s ctLNP and closed-ended DNA (ceDNA) technology for two immune cell programs and two liver programs, with an additional option for a third immune cell or liver program Moderna will fund all research and develop
Remember when they used to be free? As the US government winds down its pandemic emergency spending, health giant Moderna is preparing to shift its...
Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss Moderna CEO Stephane Bancel’s testimony before the U.S. Senate health committee.